Table 2. Association of comorbidities and adverse events with type of anesthesia.
NAD: noradrenaline; Y: yes; N: no; CNS: central nervous system; CAD: coronary artery disease; CLE: continuous lumbar epidural; LSPB: lumbar and sacral plexus block; SAB: subarachnoid block
| Type of anesthesia | |||||
| CLE (n=41) | LSPB (n=35) | SAB (n=38) | p-value | ||
| Cardiovascular | N | 5 (45.5%) | 5 (45.5%) | 1(9.1%) | p=0.163 |
| Y | 36 (35.0%) | 30 (29.1%) | 37 (35.9%) | ||
| CAD | N | 15 (22.4%) | 20 (29.9%) | 32 (47.8%) | p<0.001 |
| Y | 26 (55.3% | 15 (31.9%) | 6 (12.8%) | ||
| Respiratory | N | 31 (34.1%) | 28 (30.8%) | 32 (35.2%) | p=0.635 |
| Y | 10 (43.5%) | 7 (30.4%) | 6 (26.1%) | ||
| Endocrine | N | 14 (29.2%) | 17 (35.4%) | 17 (35.4%) | p=0.419 |
| Y | 27 (40.9%) | 18 (27.3%) | 21 (31.8%) | ||
| Renal | N | 26 (38.2%) | 24 (35.3%) | 18 (26.5%) | p=0.151 |
| Y | 15 (32.6%) | 11 (23.9%) | 20 (43.5%) | ||
| CNS | N | 28 (36.8%) | 22 (28.9%) | 26 (34.2%) | p=0.848 |
| Y | 13 (34.2%) | 13 (34.2%) | 12 (31.6%) | ||
| Malignancy | N | 37 (34.3%) | 34 (31.5%) | 37 (34.3%) | p=0.368 |
| Y | 4 (66.7%) | 1 (16.7%) | 1 (16.7%) | ||
| Electrolyte | N | 13 (27.7%) | 14 (29.8%) | 20 (42.6%) | p=0.166 |
| Y | 28 (41.85%) | 21 (31.3%) | 18 (26.9%) | ||
| Spine instrumentation, metastasis | N | 41(48.80%) | 5(5.95%) | 38(45.23%) | p<0.00001 |
| Y | 0(0) | 30(100%)) | 0(0) | ||
| NAD | N | 40 (40.4%) | 33 (33.3%) | 26 (26.3%) | p<0.001 |
| Y | 1 (6.7%) | 2 (13.3%) | 12 (80%) | ||
| Mortality | N | 40 (36.7%) | 33 (30.3%) | 36 (33%) | p=0.745 |
| Y | 1 (20%) | 2 (40%) | 2 (40%) | ||
| Cause of mortality | N | 40 (36.7%) | 33 (30.3%) | 36 (33%) | p=0.258 |
| ACS | 1 (50%) | 1 (50%) | 0 (0%) | ||
| AMI | 0 (0%) | 1 (100%) | 0 (0%) | ||
| PE | 0 (0%) | 0 (0%) | 2 (100%) | ||